Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings report highlights several negative factors: a 9% revenue decline, significant drops in instrument and lab services revenue, and decreased gross margins. Despite improved cost management and strong consumables growth, the overall financial performance is weak. The lack of a shareholder return plan and unclear management guidance further contribute to uncertainty. The Q&A session reveals limited confidence in market recovery and no specific guidance on cash burn. The positive Illumina partnership is overshadowed by broader financial challenges, leading to a likely negative stock reaction.
Key Financial Performance
Q4 2024 Revenue $46.7 million, down 9% year-over-year due to softness in Instrument and Services as CapEx constraints and cautious spending in biopharma and academia offset strong growth in Consumables.
Full Year 2024 Revenue $175.1 million, down 9% year-over-year, impacted by similar factors as Q4.
Consumables Revenue Growth Q4 2024 10% growth year-over-year, driven by strong kit sales to SomaScan-authorized sites and the Illumina early access program.
Consumables Revenue Growth Full Year 2024 18% growth year-over-year, reflecting the same drivers as Q4.
Instruments Revenue Decline Q4 2024 25% decline year-over-year, primarily due to capital spending constraints in the market.
Instruments Revenue Decline Full Year 2024 27% decline year-over-year, reflecting ongoing challenges in capital spending.
Lab Services Revenue Decline Q4 2024 18% decline year-over-year, driven by reduced project sizes from top customers.
Lab Services Revenue Decline Full Year 2024 21% decline year-over-year, with a focus on diversifying the customer base.
Field Services Revenue Decline Q4 2024 10% decline year-over-year, linked to lower instrument sales.
Field Services Revenue Decline Full Year 2024 2% decline year-over-year.
Non-GAAP Gross Margin Q4 2024 52.5%, down from 55.4% year-over-year, impacted by lower volume and instrument replacements.
Non-GAAP Gross Margin Full Year 2024 53.0%, slightly down from 53.1% in 2023.
Non-GAAP Operating Expenses Q4 2024 $42.9 million, down 24% year-over-year, due to realization of merger cost synergies.
Non-GAAP Operating Expenses Full Year 2024 $180.1 million, down 22% year-over-year, reflecting similar cost management efforts.
Adjusted EBITDA Q4 2024 $18.4 million loss, a 34% improvement year-over-year from a $28 million loss.
Adjusted EBITDA Full Year 2024 $87.3 million loss, a 33% improvement year-over-year from a $130.1 million loss.
Cash Position at Year-End 2024 Approximately $295 million, with a total cash burn of $73 million in Q4 2024.
Cash Burn Reduction Q4 2024 Adjusted cash burn plus CapEx was about $13 million, a 45% reduction versus Q3 2024.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SomaScan Platform: SomaScan is positioned as a leading platform in proteomics, utilizing a DNA aptamer-based approach to measure 10,000 proteins with unmatched precision, unlocking new possibilities in disease research and drug development.
Omics-as-a-Service: This offering leverages the full suite of solutions to deliver premium lab services, helping customers navigate capital budget constraints while accelerating product adoption.
Market Expansion: The company is expanding its customer base beyond top accounts, with revenue beyond the top five accounts growing double digits year-over-year.
Partnership with Illumina: A strategic partnership with Illumina aims to integrate DNA-based aptamer technology with Illumina's NovaSeq platform, enhancing commercial reach in proteomics.
Cost Synergies: Operationalized $80 million in cost synergies a year ahead of plan, with an additional $10 million in cost reductions implemented.
On-time Delivery: Achieved an industry-leading on-time delivery rate of 98%, up from 78% in Q4 2022.
M&A Strategy: The company plans to pursue 4 to 6 strategic transactions over the next two years, focusing on derisked technologies with clear paths to commercialization.
Shift to Higher-Margin Consumables: The company is shifting focus towards higher-margin consumables, which showed double-digit growth in Q4 2024.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: The company reported a 9% year-over-year decline in revenue for both Q4 and the full year 2024, primarily due to softness in Instrument and Services segments, attributed to capital expenditure constraints and cautious spending in biopharma and academia.
NIH Funding Reduction: There is a potential reduction in NIH spending, which could impact overall academic spending and priorities, particularly delaying capital equipment purchases. The company anticipates a mid-teens percentage decline in Americas academic revenue.
U.S.-China Trade Dynamics: The company is monitoring U.S.-China trade dynamics, including potential regulatory shifts that could impact procurement decisions, although they do not expect a direct impact on their CyTOF products.
Tariffs Impact: New import tariffs on Canada and ongoing tariffs on China could complicate the global trade environment. While the company does not expect a significant top-line impact, they estimate a low single-digit million dollar impact to gross margin and adjusted EBITDA if tariffs are absorbed.
Customer Concentration: The company has historically had high customer concentration, which has led to variability in revenue from a few large pharma accounts. They are working to diversify their customer base to mitigate this risk.
Market Conditions: The current macroeconomic environment is creating anxiety and uncertainty in the market, with expectations of a gradual market recovery and cautious optimism for 2025.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Cost Synergies: Operationalized $80 million in cost synergies, a full year ahead of plan, with an additional $10 million in cost reductions implemented.
SomaScan Platform: SomaScan is positioned as a leading technology in proteomics, with a focus on expanding its commercial adoption and partnerships, including a collaboration with Illumina.
M&A Strategy: Targeting 4 to 6 strategic transactions over the next 2 years, focusing on derisked technologies with clear paths to commercialization.
Product Mix Shift: Shifting towards higher-margin consumables and expanding into key markets.
Operational Efficiency: Continued focus on driving productivity and cost management across the business.
2025 Revenue Guidance: Anticipated organic revenue between $165 million and $175 million, reflecting a 3% decline at the midpoint.
Adjusted EBITDA Breakeven: On track for adjusted EBITDA breakeven in 2026.
Cash Position: Ended 2024 with nearly $300 million in cash, providing strength to execute strategic plans.
Market Conditions: Expecting gradual market recovery, with potential headwinds from reduced NIH spending and tariffs.
Growth Expectations: Expecting growth in instruments and SomaScan services as pharma activity and global capital spending slowly return.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: Standard BioTools has not announced any specific share buyback or dividend program during the call. However, they emphasized their commitment to maintaining a strong balance sheet with nearly $300 million in cash, which positions them to execute their strategic plan and potentially fund future acquisitions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are you hearing real time on the ground regarding the Americas due to NIH noise?
A:We are not seeing a lot yet, but anticipate that people will spend less in the Americas academia. The impact is more on the instrument side, with some effect on consumables and services.
Q:Can you provide more color on the $1 billion opportunity with the Illumina partnership?
A:There are already billions spent in proteomics, particularly in plasma proteomics. We feel comfortable with the $1 billion number for the opportunity, and expect strong Illumina revenue in '24, with growth transitioning in '25.
Q:Do you see any opportunity in China on the instrument stimulus side for your proteomics instruments?
A:We have a strong team in China and are seeing good traction, with this year looking better than last year.
Q:What is your target cash burn in '25?
A:We are not providing short-term guidance on cash burn, but you can look at the second half exit rate for improvements.
Q:If the NIH budget returns to normal, what guidance could you provide?
A:We haven't seen impact yet on sales, and we feel comfortable with the guidance we've given.
Q:What do you think the addressable market size could be for the joint product with Illumina?
A:I believe the $1 billion market estimate is conservative, as routine plasma proteomics will grow significantly over time.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on cash burn for '25, stating they are not providing short-term guidance. Additionally, while they discussed the NIH impact, they did not provide a clear answer on how a return to normal would affect guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Alex
Americas
Canada
China
Consumables
DNA aptamer
Egholm President
Field Service
Field Services
Lab Services
NIH
Nature
Phase
Slide
access
analysis
collaboration
commitment
decline
demand
development
digit
disease
dollar
drug
end market
example
exposure
forma
loss
midpoint
momentum
pharma
profitability
quality
research
return
site Illumina
spend
spending
tariff
teen
trade
validation
LAB Transcript
Standard BioTools Inc. (LAB) Q1 2025 Earnings Conference Call Transcript
Unknown5-6
The earnings call presents mixed signals: strong cost management and cash position are positive, but declining revenues, gross margins, and ongoing cash burn are concerning. The optimistic guidance and strategic partnerships offer potential upside, yet uncertainties in revenue timing and market conditions temper expectations. The Q&A session reveals cautious optimism but lacks clarity on key issues. Overall, the stock price is likely to remain neutral in the short term as positive strategic moves are counterbalanced by financial and operational challenges.
Standard BioTools Inc. (LAB) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings report highlights several negative factors: a 9% revenue decline, significant drops in instrument and lab services revenue, and decreased gross margins. Despite improved cost management and strong consumables growth, the overall financial performance is weak. The lack of a shareholder return plan and unclear management guidance further contribute to uncertainty. The Q&A session reveals limited confidence in market recovery and no specific guidance on cash burn. The positive Illumina partnership is overshadowed by broader financial challenges, leading to a likely negative stock reaction.
Standard BioTools Inc. (LAB) Q3 2024 Earnings Call Transcript
Unknown10-30
The earnings call presents a mixed picture. While there are positive developments like cost synergies and reduced cash burn, revenue decline and reliance on major customers pose risks. The partnership with Illumina and growth in consumables are positives, but weak instrument sales and cautious guidance for China offset these gains. The Q&A highlights management's cautious stance and lack of specific guidance, which could concern investors. Given these mixed signals, the stock price is likely to remain neutral in the short term.
Standard BioTools Inc. (LAB) Q2 2024 Earnings Call Transcript
Unknown8-1
The earnings call presents a mixed picture: strong partnership with Illumina, strategic capital allocation, and cost reductions are positive. However, declining revenues, gross margins, and CFO departure pose risks. The Q&A reveals management's limited transparency and reliance on a few large accounts, adding uncertainty. The share repurchase program offers some support, but overall, the mixed signals and lack of specific guidance adjustments suggest a neutral stock price movement in the short term.
LAB Slides
LAB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
